ⅢA/ⅢB期非小细胞肺癌单站持续性N2(跳跃或附加N1)多学科治疗后显著获益
该回顾性单中心研究纳入1998年1月至2015年6月诱导化疗或放化疗后手术、最终病理为非小细胞肺癌且持续性纵隔病变的145例患者。结果显示单站N2(跳跃)5年总生存率47.3%,单站N2+N1为30.2%,多站纵隔病变低于5%。结论认为肺叶或双肺叶切除可作为诱导治疗后持续性单站N2(跳跃或附加N1)患者的潜在根治选择,长期结果良好。
要点
- 单站持续性N2(跳跃)5年总生存率47.3%,附加N1为30.2%,多站病变低于5%。
- 肺叶/双肺叶切除与全肺切除5年总生存率33.5% vs 20.5%,差异无统计学意义(P=0.082)。
- 手术死亡率2.6%,并发症率35.2%,R0切除率88.3%。
核心结论
- 诱导治疗后持续性单站N2(跳跃或附加N1)患者行肺叶或双肺叶切除可获得 promising 长期生存,应考虑为潜在根治选项。
研究设计与样本
- 回顾性单中心研究,纳入1998年1月至2015年6月诱导化疗或放化疗后手术、最终病理为非小细胞肺癌且持续性纵隔病变的145例患者(93男,52女),中位年龄60岁(范围38-78)。
主要发现
- 82例(56.5%)行肺叶切除,48例(33.1%)行全肺切除,11例(7.6%)行双肺叶切除,4例(2.6%)行解剖性肺段切除;128例(88.3%)达到R0切除。
- 手术死亡率2.6%(4例),并发症率35.2%(51例)。
- 5年总生存率:单站N2(跳跃)47.3%(n=19),单站N2+N1 30.2%(n=16),多站纵隔病变低于5%(n=1)。
- 肺叶/双肺叶切除与全肺切除5年总生存率33.5% vs 20.5%,差异无统计学意义(P=0.082)。
- 5年无病生存率:ypN2a1 30.6%(n=6),ypN2a2 23.4%(n=7),ypN2b低于5%(n=1)。
临床怎么用
- 对诱导治疗后持续性单站N2(跳跃或附加N1)的非小细胞肺癌患者,可考虑肺叶或双肺叶切除作为潜在根治性治疗。
局限性
- 回顾性单中心研究,样本量有限,部分亚组事件数少,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Persistent lymph nodes infiltration after neoadjuvant treatment remains a controversial topic in the treatment of stage III non-small-cell lung cancer (NSCLC). The aim of this study is to identify subgroups with persistent N2 disease, who could experience survival benefit from the addition of surgery. METHODS: A retrospective mono-institutional study was conducted to analyse all patients with a final histopathology of NSCLC and persistent mediastinal disease after induction chemotherapy or chemoradiotherapy and surgery from January 1998 to June 2015. RESULTS: A total of 145 patients (93 men, 52 women) fulfilled the inclusion criteria. The median age was 60 years (range 38-78). A total of 82 (56.5%) patients received a lobectomy, 48 (33.1%) a pneumonectomy, 11 (7.6%) a bilobectomy and 4 (2.6%) an anatomical segmentectomy; 128 (88.3%) were completely resected (R0). Operative mortality was 2.6% (4 patients), and morbidity was 35.2% (51 patients). Overall survival at 5 years was 47.3% (n = 19) for single N2 (skip), 30.2% (n = 16) for single N2 and N1 lymph nodes and under 5% (n = 1) for multiple mediastinal stations disease. Overall survival at 5 years after lobectomy/bilobectomy was not statistically different than after pneumonectomy (33.5% vs 20.5%, P = 0.082). Disease-free survival at 5 years was 30.6% (n = 6) for ypN2a1, 23.4% (n = 7) for ypN2a2 and under 5% (n = 1) for ypN2b status. CONCLUSIONS: Lobectomy or bilobectomy has to be taken into account as a potentially curative option with promising long-term results for patients after induction treatment and persistent single-station N2 involvement (skip or additionally N1 status). TRIAL REGISTRY NUMBER: 14-6138-BO.
引用
- Stamatis G, Müller S, Weinreich G, et al. Significantly favourable outcome for patients with non-small-cell lung cancer stage IIIA/IIIB and single-station persistent N2 (skip or additionally N1) disease after multimodality treatment. Eur J Cardiothorac Surg. 2022. PMID: 34368849. doi:10.1093/ejcts/ezab372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。